Citations

Clear

5486 citation(s) found for "Yu, Stephen".

Faculty Opinions recommendation of Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 7, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717961455.793464308 Get It

Outcomes Following Radical Cystectomy for Nested Variant of Urothelial Carcinoma: A Matched Cohort Analysis
Linder, Brian J. , Frank, Igor, Cheville, John C. , Thompson, R. Houston, Thapa, Prabin , Tarrell, Robert F., Boorjian, Stephen A. , Linder, Brian J

Mayo Clinic

Journal of Urology | November 7, 2012 | Volume: 189 | Issue: 5 | Pages: 1670-1675

10.1016/j.juro.2012.11.006 | PMID 23142686 Get It

Migraine headache is present in the aura phase
Hansen, Jakob Møller , Silberstein, Stephen D., Saper, Joel R., Aurora, Sheena K. , Goadsby, Peter J. , Charles, Andrew , Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J , Charles, Andrew

Mayo Clinic

Neurology | November 1, 2012 | Volume: 79 | Issue: 20 | Pages: 2044-2049

10.1212/wnl.0b013e3182749eed | PMID 23115208 Get It

Cobalt and Chromium Measurement in Patients with Metal Hip Prostheses
Estey, Mathew P., Straeten, Catherine Van Der , Tower, Stephen S. , Hart, Alister , Moyer, Thomas P. , Diamandis, Eleftherios P.

Mayo Clinic

Clinical Chemistry | November 1, 2012 | Volume: 59 | Issue: 6 | Pages: 880-886

10.1373/clinchem.2012.193037 | PMID 23115056 Get It

Percutaneous Renal Cryoablation After Partial Nephrectomy: Technical Feasibility, Complications and Outcomes
Hegg, Ryan, Schmit, Grant D. , Boorjian, Stephen A. , McDonald, Robert J. , Weisbrod, Adam J. , Callstrom, Matthew R. , Atwell, Thomas D. , Thompson, R. Houston, Kurup, A. Nicholas

Mayo Clinic

Journal of Urology | October 30, 2012 | Volume: 189 | Issue: 4 | Pages: 1243-1248

10.1016/j.juro.2012.10.066 | PMID 23123377 Get It

Mesenchymal Stem Cells and Endothelial Progenitor Cells Decrease Renal Injury in Experimental Swine Renal Artery Stenosis Through Different Mechanisms
Zhu, Xiang-Yang, Urbieta-Caceres, Victor H., Krier, James D., Textor, Stephen C., Lerman, Lilach O. , Lerman, Amir

Mayo Clinic

Stem Cells | October 23, 2012 | Volume: 31 | Issue: 1 | Pages: 117-125

10.1002/stem.1263 | PMID 23097349 Get It

Abstract Endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) augment tissue repair but possess slightly different properties. How the cellular phenotype affects the efficacy of this approach in renovascular disease is incompletely understood. This study tested the hypothesis that EPC and MSC protect the poststenotic kidney by blunting different disease pathways. Peripheral blood EPC and adipose-derived MSC were expanded and characterized by cell surface markers (e.g., CD34/kinase insert domain receptor, or CD44/CD90). Single-kidney hemodynamics and function were assessed in pigs after 10 weeks of renal artery stenosis (RAS) treated 4 weeks earlier with an intrarenal infusion of vehicle (n = 7), EPC (RAS+EPC) or MSC (RAS+MSC) (both 10 × 106, n = 6), and normal controls (n = 7). Kidney disease mechanisms were evaluated ex vivo. The ability of EPC and MSC to attenuate endoplasmic reticulum (ER) stress was also studied in isolated ER and in tubular cells cocultured with EPC and MSC. Glomerular filtration rate in RAS was lower than controls, increased in RAS+EPC, and further improved in RAS+MSC, although both improved renal blood flow similarly. EPC prominently enhanced renal growth factor expression and decreased oxidative stress, while MSC more significantly attenuated renal inflammation, ER stress, and apoptosis. Furthermore, MSC induced a greater decrease in caspase-3 and CHOP expression in cultured tubular cells through mechanisms involving cell contact. EPC and MSC achieve a comparable decrease of kidney injury in RAS by different mechanisms, although MSC elicited slightly superior improvement of renal function. These results support development of cell-based approaches for management of renovascular disease and suggest cell selection based on the underlying pathophysiology of kidney injury.
Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis
Kim, Simon P. , Thompson, R. Houston, Boorjian, Stephen A. , Han, Leona C., Erwin, Patricia J., Costello, Brian A. , Chow, George K. , Leibovich, Bradley C. , Murad, M. Hassan , Weight, Christopher

Mayo Clinic

Journal of Urology | October 22, 2012 | Volume: No volume available | Issue: 1 | Pages: No page available

10.1016/j.juro.2012.10.026 | PMID 23085064 Get It

Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology
Basch, Ethan , Mullins, C. Daniel , Smith, Mary Lou , Coons, Stephen Joel , Sloan, Jeff A. , Wenzel, Keith W., Chauhan, Cynthia, Eppard, Wayland, Lipscomb, Joseph , Raymond, Stephen A., Spencer, Merianne, Tunis, Sean , Basch, Ethan , Abernethy, Amy P. , Reeve, Bryce B. , Frank, Elizabeth S.

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 30 | Issue: 34 | Pages: 4249-4255

10.1200/jco.2012.42.5967 | PMID 23071244 Get It

Examining the patient's subjective experience in prospective clinical comparative effectiveness research (CER) of oncology treatments or process interventions is essential for informing decision making. Patient-reported outcome (PRO) measures are the standard tools for directly eliciting the patient experience. There are currently no widely accepted standards for developing or implementing PRO measures in CER. Recommendations for the design and implementation of PRO measures in CER were developed via a standardized process including multistakeholder interviews, a technical working group, and public comments. Key recommendations are to include assessment of patient-reported symptoms as well as health-related quality of life in all prospective clinical CER studies in adult oncology; to identify symptoms relevant to a particular study population and context based on literature review and/or qualitative and quantitative methods; to assure that PRO measures used are valid, reliable, and sensitive in a comparable population (measures particularly recommended include EORTC QLQ-C30, FACT, MDASI, PRO-CTCAE, and PROMIS); to collect PRO data electronically whenever possible; to employ methods that minimize missing patient reports and include a plan for analyzing and reporting missing PRO data; to report the proportion of responders and cumulative distribution of responses in addition to mean changes in scores; and to publish results of PRO analyses simultaneously with other clinical outcomes. Twelve core symptoms are recommended for consideration in studies in advanced or metastatic cancers. Adherence to methodologic standards for the selection, implementation, and analysis/reporting of PRO measures will lead to an understanding of the patient experience that informs better decisions by patients, providers, regulators, and payers.
Automated Vulnerability Testing Identifies Patients With Inadequate Defibrillation Safety Margin
Birgersdotter‐Green, Ulrika , Ruetz, Linda L., Anand, Kishlay, Monir, George , Abeyratne, Athula, Bailey, J. Russell, Shorofsky, Stephen R., Hsia, Henry H. , Friedman, Paul A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | October 11, 2012 | Volume: 5 | Issue: 6 | Pages: 1073-1080

10.1161/circep.112.971275 | PMID 23051838 Get It

Background— Implantable cardioverter-defibrillator system efficacy is tested at implant by induction of ventricular fibrillation (VF). Defibrillation safety margin can be assessed without VF induction using upper limit of vulnerability methods, but these methods have required manual determination of T-wave timing. Methods and Results— To test the feasibility of an inductionless system of implant testing, a multicenter prospective study of an automated vulnerability safety margin system was conducted, which measured T-wave timing using an intracardiac electrogram during a ventricular pacing train. The system delivered up to 4 T-wave shocks of 18 J. Lack of VF induction by all 4 shocks was considered evidence of defibrillation adequacy. Patients subsequently underwent conventional defibrillation testing to meet a standard implant criterion. The 95% lower CI for defibrillation success at 25 J for noninduced patients was found using Bayesian statistics. Sixty patients were enrolled at 6 centers. Vulnerability testing and defibrillation success results were obtained from 54 patients. Vulnerability testing induced VF in 10 (19%) patients, of whom 2 required system revision. All patients not induced by vulnerability testing were successfully defibrillated twice at ≤25 J. The Bayesian credible interval was 97% to 100% for the population success rate of defibrillation at 25 J for automated vulnerability safety margin noninduced patients. Conclusions— An automated system identified all patients who failed conventional safety margin testing, while inducing only 19% of patients. Although limited by sample size, this study suggests the feasibility of automated implant testing that substantially reduces the need for VF induction in patients receiving implantable cardioverter-defibrillators.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Boxer, Adam L. , Huey, Edward D. , Hu, William T. , Rosen, Howard J. , Kramer, Joel H. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J., Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Jackson, George R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Abushakra, Susan, Lewcock, Joseph W. , Farese, Robert V. , Kenet, Robert O. , LaFerla, Frank M. , Perrin, Steve, Whitaker, Steve, Grossman, Murray, Gold, Michael , Kao, Aimee W. , Knopman, David S. , Honig, Lawrence S. , Mesulam, Marsel M. , Boeve, Bradley F. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H , Hu, William T.

Mayo Clinic

Alzheimer's & Dementia | October 10, 2012 | Volume: 9 | Issue: 2 | Pages: 189-198

10.1016/j.jalz.2012.03.003 | PMID 23062850 Get It

Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.